10x Genomics Bolsters Commercial Leadership with the Appointment of Bradford J. Crutchfield as Chief Commercial Officer

February 8, 2017

PLEASANTON, Calif. – February 9, 2017 – 10x Genomics, a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced the appointment of Bradford J. Crutchfield as chief commercial officer of the company. Mr. Crutchfield will oversee global sales, marketing, business development and customer support. John Pouk, the company's interim chief commercial officer, will work closely with Mr. Crutchfield in his new role as senior vice president, global sales and commercial operations.

"10x aims to power the discoveries that will accelerate the next wave of innovation in precision medicine," said Serge Saxonov, co-founder and chief executive officer of 10x Genomics. "Brad's 30-plus years of life science industry experience and specific focus on technology adoption within academic and pharma research laboratories will help drive our expansion into these markets. Coupled with John's unparalleled industry experience, 10x is poised to realize significant growth in 2017 and beyond."

Mr. Crutchfield brings more than 30 years of experience in commercial sales and marketing leadership to the company. Prior to joining 10x Genomics, Mr. Crutchfield served as QIAGEN's senior vice president, life sciences business area, expanding their presence in the academic, pharmaceutical and applied testing industries. Prior, he served as vice president and general manager, Europe, Middle East & Africa, for Illumina. From 1985 to 2014, Mr. Crutchfield held positions of increasing responsibility with Bio-Rad Laboratories Inc., rising to executive vice president and president of the Life Science Group. In 2013 and 2014 he was a director of NanoString Technologies, Inc. Mr. Crutchfield holds a Bachelor of Science in Physiology from the University of California, Davis.

"10x has created an emerging segment in genomic analysis with their Chromium System," said Mr. Crutchfield. "As academia and pharma seek new, sophisticated technologies to answer biology's most complex questions, 10x has the unique opportunity to become a true partner in those discoveries. I look forward to working with this exceptional team to drive continued commercial growth in a new wave of single cell, genome and exome applications."

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes and other valuable genomic information with comprehensive workflows for Single Cell, Genome, Exome and *de novo* Assembly applications that incorporate their pre-existing sequencing technologies.

www.10xGenomics.com

Media Contact

Julia Baron
Pure Communications
(415) 658-9766
jbaron@purecommunications.com

Investor Contact

Matt Clawson
Pure Communications
(949) 370-8500
mclawson@purecommunications.com